Prelude Capital Management, LLC Nuvation Bio Inc. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $32,920 - $47,084	-12,760 Reduced 25.93%	36,440 $106,000
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $71,832 - $195,324	49,200 New	49,200 $179,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.1 $41,040 - $68,401	-32,572 Reduced 49.73%	32,932 $44,000
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $12,902 - $15,218	-8,271 Reduced 11.21%	65,504 $117,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $3,886 - $6,023	-2,429 Reduced 3.19%	73,775 $122,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $39,480 - $58,750	23,500 Added 44.59%	76,204 $146,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $15,284 - $212,924	52,704 New	52,704 $118,000
Q2 2021 Aug 16, 2021	SELL	$9.22 - $14.48 $117,665 - $184,793	-12,762 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.0 - $14.57 $114,858 - $185,942	12,762 New	12,762 $133,000

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.